3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
19
Active not recruiting
8
Suspended
2
Not yet recruiting
2
Completed
2
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
8
Carboplatin
7
Pemetrexed
5
Nivolumab
5
Cyclophosphamide
5
Cisplatin
5
ixazomib
4
durvalumab
4
Specimen Handling
4
Paclitaxel
4
Bevacizumab
4
ibrutinib
3
fludarabine phosphate
3
fludarabine
3
Ipilimumab
3
Gemcitabine
3
Docetaxel
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
tislelizumab
2
temsirolimus
2
evolocumab
2
enzalutamide
2
daratumumab
2
atezolizumab
2
Trastuzumab
2
Tomography, X-Ray Computed
2
Standard of Care
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Surgical Procedures, Operative
×
30 days
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled